This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

Also separately, Lilly said it would increase its dividend by 10.6% to 47 cents a share, affecting an increase in the annual dividend rate to $1.88 a share. Lilly was trading up 72 cents, or 1.3%, at $53.87.

In another deal, Royal Phillips (PHG - Get Report) said it would buy health-care information company Visicu (EICU) for $430 million, or $12 a share. The price is a 35% premium to Visicu's closing price on December 17. Visicu makes remote monitoring technology and clinical intelligence products. The company's board unanimously approved the deal, which is now subject to shareholder vote. The transaction is expected to close in the first quarter of next year.

Visicu added $2.88, or 32.5%, to $11.74. Royal Philips was trading up 58 cents, or 1.4%, at $42.90.

Also, Cyberonics (CYBX) said that it entered into an agreement with Ethicon Endo-Surgery granting exclusive rights to the company's patents and patent applications related to vagus nerve stimulation (VNS) for the treatment of obesity, diabetes and hypertension in overweight patients. Ethicon Endo-Surgery will pay Cyberonics a signing fee of $9.5 million and royalties on commercial sales of products covered by the subject patents. Cyberonics' were up 42 cents, or 3.6%, to $12.11.

Elsewhere, Vasogen (VSGN) said the results of its late stage trial on its Celacade System in patients with chronic heart failure have been accepted for publication in The Lancet. The company previously announced that the Celacade therapy reduced the risk of death or cardiovascular hospitalizations for a large pre-specified subgroup of patients with heart failure by 39% compared to placebo. Shares were trading up 35 cents, or 19.7%, at $2.13.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CYBX $69.95 1.24%
EPIX $2.91 0.00%
ESMC $0.73 -2.70%
LLY $74.58 -0.92%
PHG $26.55 0.76%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs